Key result
Multivessel PCI linked to ~41% lower 1-year mortality versus IRA-only PCI in STEMI cardiogenic shock.
Why the study?
Evidence on the benefit of multivessel PCI over IRA-only PCI in patients with STEMI multivessel disease presenting with cardiogenic shock was limited.
Cohort (n=659)
Yes
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“It is just a registry, and registries are always prone to bias and usually lead to misleading results in comparison to a randomized trial such as CULPRIT-SHOCK. This is why we performed CULPRIT-SHOCK.”
“We respect results from the randomized controlled trial. However, registry data can give us valuable insights, too.”
“Taking into account the low aortic pressure and high left ventricular end-diastolic pressure seen in cardiogenic shock, multivessel PCI may at least theoretically improve myocardial perfusion and hence improve myocardial function, systemic circulation, and recovery from shock.”
Prospective cohort study shows reduced one-year mortality with multivessel PCI in STEMI patients with cardiogenic shock, indicating a survival benefit from complete revascularization.
BACKGROUND: Recent trials demonstrated a benefit of multivessel percutaneous coronary intervention (PCI) for noninfarct-related artery (non-IRA) stenosis over IRA-only PCI in patients with ST-segment elevation myocardial infarction (STEMI) multivessel disease. However, evidence is limited in patients with cardiogenic shock. OBJECTIVES: This study investigated the prognostic impact of multivessel PCI in patients with STEMI multivessel disease presenting with cardiogenic shock, using the nationwide, multicenter, prospective KAMIR-NIH (Korea Acute Myocardial Infarction-National Institutes of Health) registry. METHODS: Among 13,104 consecutive patients enrolled in the KAMIR-NIH registry, we selected patients with STEMI with multivessel disease presenting with cardiogenic shock and who underwent primary PCI. Primary outcome was 1-year all-cause death, and secondary outcomes included patient-oriented composite outcome (a composite of all-cause death, any myocardial infarction, and any repeat revascularization) and its individual components. RESULTS: A total of 659 patients were treated by multivessel PCI (n = 260) or IRA-only PCI (n = 399) strategy. The risk of all-cause death and non-IRA repeat revascularization was significantly lower in the multivessel PCI group than in the IRA-only PCI group (21.3% vs. 31.7%; hazard ratio: 0.59; 95% confidence interval: 0.43 to 0.82; p = 0.001; and 6.7% vs. 8.2%; hazard ratio: 0.39; 95% confidence interval: 0.17 to 0.90; p = 0.028, respectively). Results were consistent after multivariable regression, propensity-score matching, and inverse probability weighting to adjust for baseline differences. In a multivariable model, multivessel PCI was independently associated with reduced risk of 1-year all-cause death and patient-oriented composite outcome. CONCLUSIONS: Of patients with STEMI and multivessel disease with cardiogenic shock, multivessel PCI was associated with a significantly lower risk of all-cause death and non-IRA repeat revascularization. Our data suggest that multivessel PCI for complete revascularization is a reasonable strategy to improve outcomes in patients with STEMI with cardiogenic shock.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) conducted a cohort in STEMI with multivessel disease presenting with cardiogenic shock (n=659). Multivessel PCI vs. Infarct-related artery (IRA)-only PCI was evaluated on 1-year all-cause death (HR 0.59, 95% CI 0.43 to 0.82, p=0.001). In patients with STEMI and cardiogenic shock, multivessel PCI was associated with a lower risk of 1-year all-cause death compared to IRA-only PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: